SpringWorks Therapeutics Inc. in Stamford, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, recently announced that Mike Burgess, M.B.Ch.B., Ph.D., has been appointed head of research and development (R&D). Burgess is a physician-scientist with clinical experience in pediatrics and pediatric oncology and more than 20 years in the pharmaceutical industry. He will lead the R&D effort as the company continues to advance its diversified targeted oncology pipeline and to expand its portfolio with additional oncology programs. He succeeds Stephen Squinto, Ph.D., who served as acting head of R&D since the company”™s launch in 2017. He will continue to serve on the SpringWorks Board of Directors.
“At SpringWorks, we are driven to execute on our ambitious plans to provide oncology patients with transformative new therapies, and our portfolio of programs is continuing to mature and expand in service of that goal,” said Saqib Islam, CEO. “”¦I look forward to the further scientific, clinical and leadership excellence he (Burgess) will bring to our already strong team as we continue to build a world-class oncology company on behalf of a broad range of oncology patients.”
Burgess joins SpringWorks from Turnstone Biologics, where he was president of R&D and led the buildout of a leading cancer immunotherapy R&D organization. Prior to Turnstone, he was with Bristol-Myers Squibb and before that, he held several different senior leadership positions at Hoffmann La-Roche. Burgess received his medical degree M.B.Ch.B. and Ph.D. in molecular biology from the University of Bristol, United Kingdom and spent 10 years as a practicing physician in pediatrics and pediatric oncology.
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer.
